Lymphomas & Lymphoid Neoplasia

Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

Venetoclax Outperforms Standard Chemo-Immunotherapy in the Treatment of Relapsed/Refractory CLL

Treatment with the BCL2 inhibitor venetoclax and rituximab led to deeper and more durable responses than the combination of bendamustine and rituximab in patients...
WIB_icon

International Workshop on CLL Updates Guidelines for the Design and Conduct of Clinical Trials

Prompted by advances in the biology and treatment of patients with chronic lymphocytic leukemia (CLL), the National Cancer Institute–sponsored International Workshop on CLL has...

Weighing the Global Cancer Burden: CONCORD-3 Finds Cancer Survival Varies by Location

Five-year cancer survival rates are increasing globally, but disparities exist between regions, according to results from the CONCORD-3 global cancer surveillance program published in...
WIB_icon

Five-Year Follow-Up Shows Response to Ibrutinib Deepens Over Time for CLL Patients

Treatment with continuous, single-agent ibrutinib led to durable responses in patients with chronic lymphocytic leukemia (CLL), even among previously untreated patients, patients older than...
WIB_icon

Treatment With Blinatumomab Eradicates MRD in Patients with ALL

More than three-quarters of patients with acute lymphocytic leukemia (ALL) who were in complete remission (CR) following chemotherapy but still had evidence of minimal...

Early-Phase Study Finds Venetoclax Plus Obinutuzumab Safe and Effective in Patients with Untreated CLL

Venetoclax – a highly selective, potent BCL2 inhibitor – demonstrated significant anti-tumor activity in patients with chronic lymphocytic leukemia (CLL), both as monotherapy and...
WIB_icon

Ibrutinib Treatment May Predispose to Fungal Infections, Study Cautions

Although previous research has demonstrated that ibrutinib is associated with fewer infectious complications than standard chemotherapy in patients with chronic lymphocytic leukemia (CLL), a...
WIB_icon

Early-Phase Study Finds Duvelisib Active in Variety of Advanced Hematologic Malignancies

The oral phosphoinositide 3-kinase (PI3K) dual inhibitor duvelisib appeared to be active and tolerable at a range of doses and across a variety of...

No Survival Benefit With Adding Rituximab to Ibrutinib in Patients With Chronic Lymphocytic Leukemia

In a randomized, open-label, single-center, phase II study, researchers found that the addition of rituximab to ibrutinib did not improve progression-free survival (PFS; primary...

Patients With CLL Willing to Trade Treatment Efficacy for Reduced Costs and Adverse Events

Some patients living with chronic lymphocytic leukemia (CLL) are willing to accept drugs that are less effective in exchange for reduced adverse events (AEs)...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.